- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04746911
Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-216)
March 7, 2023 updated by: Arcutis Biotherapeutics, Inc.
An Open Label, 4-Week, Phase 2, Maximal Usage Pharmacokinetics and Safety Study of ARQ-151 Cream 0.3% Administered QD in Pediatric Subjects (Ages 2 to 5 Years Old) With Plaque Psoriasis
This is a Phase 2, open label, maximal usage PK and safety study of ARQ-151 cream 0.3% in pediatric subjects (ages 2 to 5 years old) with plaque psoriasis:
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
10
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 1X8
- Arcutis Clinical Site 621
-
-
-
-
-
Santo Domingo, Dominican Republic
- Arcutis Clinical Site 630
-
-
-
-
Alabama
-
Mountain Brook, Alabama, United States, 35223
- Arcutis Clinical Site 603
-
-
Arizona
-
Scottsdale, Arizona, United States, 85255
- Arcutis Clinical Site 604
-
-
California
-
Fountain Valley, California, United States, 92708
- Arcutis Clinical Site 609
-
Los Angeles, California, United States, 90017
- Arcutis Clinical Site 618
-
Los Angeles, California, United States, 90057
- Arcutis Clinical Site 608
-
Rancho Santa Margarita, California, United States, 92688
- Arcutis Clinical Site 611
-
-
Florida
-
Boca Raton, Florida, United States, 33428
- Arcutis Clinical Site 610
-
Coral Gables, Florida, United States, 33146
- Arcutis Clinical Site 602
-
Delray Beach, Florida, United States, 33484
- Arcutis Clinical Site 613
-
Miami, Florida, United States, 33125
- Arcutis Clinical Study Site 628
-
Miami, Florida, United States, 33155
- Arcutis Clinical Site 607
-
-
Indiana
-
West Lafayette, Indiana, United States, 47906
- Arcutis Clinical Site 627
-
-
Texas
-
Arlington, Texas, United States, 76001
- Arcutis Clinical Site 606
-
Frisco, Texas, United States, 75034
- Arcutis Clinical Site 619
-
Frisco, Texas, United States, 75034
- Arcutis Clinical Study Site 619
-
Houston, Texas, United States, 77030
- Arcutis Clinical Site 605
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
2 years to 5 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Informed consent of parent(s) or legal guardian.
- Males or females, 2 to 5 years old (inclusive).
- Clinical diagnosis of psoriasis vulgaris of at least 2 months duration as determined by the Investigator or through subject interview. Stable disease for the past 3 weeks.
- Psoriasis vulgaris on the face, extremities, trunk, and/or intertriginous areas involving at least 2% of BSA (excluding the scalp, palms, and soles).
- An Investigator Global Assessment of disease severity (IGA) of at least Mild ('2') at Baseline.
- Subject has adequate venous access for PK sampling in areas not involved by plaque psoriasis and not being treated with ARQ-151 (e.g., back of the hands).
- In good health as judged by the Investigator, based on medical history, physical examination, 12-lead electrocardiogram (ECG), serum chemistry labs and hematology values.
- Subjects and parent(s)/legal guardian(s) are considered reliable and capable of adhering to the Protocol and Visit Schedule, according to the judgment of the Investigator.
Exclusion Criteria:
- Subjects with any serious medical or psychiatric condition or clinically significant laboratory, ECG, vital signs, or physical examination abnormality that would prevent study participation or place the subject at significant risk, as judged by the Investigator.
- Planned initiation or changes to concomitant medication that could, in the opinion of the Investigator, affect psoriasis vulgaris
- Current diagnosis of non-plaque form of psoriasis (e.g., guttate, erythrodermic/exfoliative, palmoplantar only involvement, or pustular psoriasis). Current diagnosis of drug-induced psoriasis.
- Subjects with any condition on the treatment area which, in the opinion of the Investigator, could confound efficacy measurements.
- Subjects who cannot discontinue the use of strong cytochrome P-450 CYP3A4 inducers for 2 weeks prior to Baseline/Day 1and during the study period.
- Subjects who cannot discontinue the use of strong cytochrome P-450 CYP3A4 inhibitors for 2 weeks prior to Baseline/Day 1 and during the study period.
- Subjects who are unwilling to refrain from prolonged sun exposure and from using a tanning bed or other artificial light emitting devices (LEDs) for 4 weeks prior to Baseline/Day 1 and during the study.
- Subjects who cannot discontinue specific systemic therapies and/or topical therapies prior to the Baseline/Day 1 and during the study period according to the protocol.
- Subjects with any infection requiring oral or intravenous administration of antibiotics, antifungal or antiviral agents within 2 weeks prior to Baseline/Day 1.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ARQ-151 cream 0.3%
Open label study of ARQ-151 cream 0.3% applied once daily for 4 weeks
|
ARQ-151 cream 0.3% applied to chronic plaque psoriasis lesions once a day for 4 weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Plasma pharmacokinetic (PK) profile of ARQ-151 cream 0.3% and its major N-oxide metabolite
Time Frame: Week 4
|
Plasma levels of circulating roflumilast and its major N-oxide metabolite
|
Week 4
|
Incidence of adverse events
Time Frame: Week 4
|
Number of participants with adverse events during treatment will be assessed
|
Week 4
|
Incidence of application site reactions
Time Frame: Week 4
|
Number of subjects that experience an application site skin reaction by investigator assessment and application site reactions reported as adverse events will be assessed
|
Week 4
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 1, 2021
Primary Completion (Actual)
May 11, 2022
Study Completion (Actual)
May 11, 2022
Study Registration Dates
First Submitted
February 5, 2021
First Submitted That Met QC Criteria
February 5, 2021
First Posted (Actual)
February 10, 2021
Study Record Updates
Last Update Posted (Estimate)
March 10, 2023
Last Update Submitted That Met QC Criteria
March 7, 2023
Last Verified
March 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ARQ-151-216
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Psoriasis
-
ProgenaBiomeRecruitingPsoriasis | Psoriasis Vulgaris | Psoriasis of Scalp | Psoriatic Plaque | Psoriasis Universalis | Psoriasis Face | Psoriasis Nail | Psoriasis Diffusa | Psoriasis Punctata | Psoriasis Palmaris | Psoriasis Circinata | Psoriasis Annularis | Psoriasis Genital | Psoriasis GeographicaUnited States
-
Clin4allRecruitingPsoriasis of Scalp | Psoriasis Nail | Psoriasis Palmaris | Psoriasis Genital | Psoriasis PlantarisFrance
-
Innovaderm Research Inc.CompletedScalp Psoriasis | Pustular Palmo-plantar Psoriasis | Non-pustular Palmo-plantar Psoriasis | Elbow Psoriasis | Lower Leg PsoriasisCanada
-
Centre of Evidence of the French Society of DermatologyRecruitingPsoriasis | Psoriasis Vulgaris | Psoriasis of Scalp | Psoriatic Plaque | Psoriasis Universalis | Psoriasis Palmaris | Psoriatic Erythroderma | Psoriatic Nail | Psoriasis Guttate | Psoriasis Inverse | Psoriasis PustularFrance
-
UCB Biopharma S.P.R.L.CompletedModerate to Severe Psoriasis | Generalized Pustular Psoriasis and Erythrodermic PsoriasisJapan
-
AmgenCompletedPsoriasis-Type Psoriasis | Plaque-Type PsoriasisUnited States
-
Janssen Pharmaceutical K.K.RecruitingGeneralized Pustular Psoriasis | Erythrodermic PsoriasisJapan
-
Eli Lilly and CompanyCompletedGeneralized Pustular Psoriasis | Erythrodermic PsoriasisJapan
-
TakedaRecruitingGeneralized Pustular Psoriasis | Erythrodermic PsoriasisJapan
-
Herlev and Gentofte HospitalRecruitingMyocardial Infarction | Myocardial Ischemia | Heart Diseases | Cardiovascular Diseases | Heart Failure | Stroke | Psoriasis | Heart Failure, Diastolic | Psoriasis Vulgaris | Cardiovascular Risk Factor | Heart Failure, Systolic | Left Ventricular Dysfunction | Psoriasis Universalis | Psoriasis Face | Psoriasis Diffusa | Psoriasis... and other conditionsDenmark
Clinical Trials on ARQ-151 cream 0.3%
-
Arcutis Biotherapeutics, Inc.CompletedChronic Plaque PsoriasisUnited States, Canada
-
Arcutis Biotherapeutics, Inc.CompletedPlaque PsoriasisUnited States
-
Arcutis Biotherapeutics, Inc.CompletedChronic Plaque PsoriasisUnited States, Canada
-
Arcutis Biotherapeutics, Inc.CompletedChronic Plaque PsoriasisUnited States, Canada, Dominican Republic
-
Arcutis Biotherapeutics, Inc.CompletedMaximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-215)Psoriasis | Plaque PsoriasisUnited States, Canada, Dominican Republic
-
Arcutis Biotherapeutics, Inc.CompletedPsoriasisCanada, United States
-
Arcutis Biotherapeutics, Inc.CompletedAtopic Dermatitis (Eczema)United States
-
Arcutis Biotherapeutics, Inc.Active, not recruitingAtopic Dermatitis EczemaUnited States, Canada
-
Arcutis Biotherapeutics, Inc.CompletedPlaque PsoriasisUnited States, Canada
-
Arcutis Biotherapeutics, Inc.CompletedAtopic Dermatitis EczemaUnited States, Canada